Nektar Therapeutics issued a statement in response to Pfizer's announcement this morning to exit Exubera, the inhaled insulin product to treat diabetes.
"We first learned this morning of Pfizer's decision to walk away from Exubera from their press release," said Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics.
"Nektar has been very disappointed in Pfizer's performance in marketing Exubera. Pfizer has publicly acknowledged its organizational difficulties and resulting poor performance in launching Exubera.
This has culminated in their announcement today.
We are evaluating all of our options with respect to Pfizer's Exubera announcement to protect the interests of Nektar. We continue to believe Exubera is an important advancement for diabetic patients."
No comments:
Post a Comment